What wildlife could be reservoirs for SARS-CoV-2?
New paper suggests North American big brown bats are not. Here's why this is important & why we need more studies like this.
Thread
onlinelibrary.wiley.com/doi/10.1111/tb…
We still don't know the natural reservoir for SARS-CoV-2. Some similar viruses were found in horseshoe bats (Rhinolophus spp.), but the difference between those viruses & SARS-CoV-2 is large enough that SARS-CoV-2 may have different reservoir.
ncbi.nlm.nih.gov/pmc/articles/P…
Regardless of where SARS-CoV-2 originally came from, many have worried that SARS-CoV-2 might be transmitted from humans into other animals that might be able to sustain the virus & transmit it back to humans.
Most worrisome, the virus might evolve in animals hosts to become more deadly, more transmissible, or able to infect a person vaccinated with the current set of vaccines being developed or immune from previous infection.
Which animals do we know can get infected & which can transmit virus to other animals?
Susceptible & Infectious*: felids, mustelids (mink, ferrets), Rousettus bats, primates, hamsters, shrews, mice
Susc., not Infect: dogs, cows
Not Susc.: Pigs, chickens, ducks
* see next tweet
*Note that experimental infection data CANNOT indicate whether a species can maintain the virus in a population; only whether they can become infected & shed live virus. These are necessary but NOT sufficient conditions for species being a reservoir for a pathogen.
Several papers have also tried to use models based on binding to ACE receptors to predict susceptibility but these models poorly match experimental studies (onlinelibrary.wiley.com/doi/10.1111/tb…).
However, experimental infections are hard to do & people worry there may be many other animal species that are susceptible & infectious & some *could* become reservoirs.
One obvious group people have worried about is bats. Of special concern is bats in the Americas, since they would be novel hosts for the virus. (Old world bats might also be a novel host or might be a/the natural reservoir; we don't know yet).
A large group of scientists who have worked on bats tried to assess the risk of spillover of SARS-CoV-2 from humans to bats & especially North American bats. But they had no actual data on SARS-CoV-2, so it was just speculation.
journals.plos.org/plospathogens/…
This new paper (w/ one shared author from paper in last tweet; Hon Ip) found that big brown bats were completely resistant to infection. No evidence of infection or transmission to cage mates.
onlinelibrary.wiley.com/doi/10.1111/tb…
What does this mean for N American bats serving as reservoirs for SARS-CoV-2? Strictly, it only implies that this single species is unlikely to be a host. Extrapolating to other groups (e.g. abundant Myotis & Tadarida) could be risky.
However, since we can't test all species, one might ask why we should suspect, a priori, that North American bats are likely to be competent hosts for SARS-CoV-2? Some papers that have done so (e.g. biorxiv.org/content/10.110…) were clearly wrong about big brown bats & SARS-CoV-2.
The failure of multiple papers using indirect assessments (ACE receptors, trait based models, etc.) to correctly identify hosts for SARS-CoV-2 clearly indicates these indirect approaches have poor accuracy at the species level.
Why does this matter? B/c quantifying the risk that a species or taxa could be a reservoir determines what measures we should take to avoid human-animal interactions.
There are variable levels of contact b/w humans & different animal taxa & the chance of virus spillover (& spillback) depends on contact rates & chance animal can sustain virus. For high risk species we clearly should avoid contact.
For farmed mink, risk was clearly high (spillover, spillback & viral evolution in animal host demonstrated), so millions were culled & many have suggested mink farming be outlawed.
nytimes.com/2020/11/04/hea…
What about other species? Few, if any, have been shown to be as high risk as mink. Should we try to stop all contact b/w humans & all animals known or suspected to be possible hosts? This would mean no contact w/ cats, weasles, mice, primates. Clearly this would be difficult &
it hasn't happened for any of these groups.

But research on N American bats, including work on the biggest current threat to hibernating bats, white-nose syndrome, has been stopped in many (but not all) places. Is this justified? It is clearly a risk-benefit tradeoff.
Hard evidence for risk is absent, so far, & new paper shows it is clearly lower than suggested by indirect modeling papers. Conservation benefit of halted research & monitoring is important, but hard to put in the same currencies (public health vs wildlife conservation).
New paper should be used to revise risk-benefit assessments, especially given total absence of data in previous assessment (journals.plos.org/plospathogens/…).
Summary
Identifying potential animal reservoirs for a novel pathogen like SARS-CoV-2 that can both infect & transmit among widely disparate mammalian taxa including primates, felids, weasels & hamsters is difficult. Indirect approaches do a poor job identifying competent hosts...
but experimental infections are difficult so we can't examine most species or taxa.

Restricting contact (closing/culling mink farms, avoiding contact w/ domestic pets, stopping research or animal rehabilitation) has costs. Rigorous cost-benefit assessments are difficult.
I'm grateful for work like new paper & hope for more studies on other taxa that could lead to better assessment of risks & benefits.
In meantime, people contacting animals should reduce transmission risk, like we do b/w humans, w/ PPE, isolating when sick, etc.

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with A Marm Kilpatrick

A Marm Kilpatrick Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @DiseaseEcology

14 Dec
Why do we exclude groups from vaccine trials (pregnant, lactating women, people w/ anaphylactic reactions) & then allow vaccination of them based on trials? Isn't this recipe for possibly very bad outcomes? Urgent remedy needed.
Thread
nytimes.com/2020/12/11/hea…
Pfizer/BioNtech vaccine was just granted EUA from FDA. EUA does not exclude any groups, except children under 16.
fda.gov/media/144412/d…
CDC met today & also recommended vaccination w/out clear exclusions for groups excluded (e.g. pregnant women).
cnbc.com/2020/12/12/cdc…
But who was excluded from phase 3 trial? Many groups!
Pregnant/breastfeeding women
History of anaphylaxis
Immunocompromised
Those being treated w/ corticosteriods
etc.
Read 8 tweets
13 Dec
Who should be vaccinated next?
1st batch Pfizer/BioNTech vaccine is shipping & will go to HCW + nursing homes as it should. But next tier is debated (essential workers? elderly? pre-existing morbidities?).
Model suggests elderly for decreasing deaths but more info needed
Thread
FDA & CDC have given green light for Pfizer/BioNTech vaccine. Supplies are very limited initially & transmission is raging so it's important to choose carefully in who to vaccinate first. How can we determine what is best? Mathematical models!
A very nice paper by @bubar_kate @DanLarremore @StephenKissler @sarahcobey @yhgrad @mlipsitch tries to determine which age group should be prioritized to minimize deaths, years of life lost, and total incidence.
medrxiv.org/content/10.110…
Read 15 tweets
8 Dec
Vaccine distribution w/ fragile vaccine is hard.

Pfizer's vaccine needing a -80C freezer is making it hard to get it to the most needy people. And shipping containers of 975 doses are making it harder still.
Short thread
Everyone is understandably excited about Pfizer/BioNTech vaccine, w/ 95% efficacy against symptomatic cases (but data not so clear for severe infections: ). Now, we need to get it to the people most in need & fast.
Why fast? B/c there are 200K new cases/day in US (maybe 800K infections/day () & ~600K globally? About 0.5-1% of these infections will lead to death (
) a month from now. So time is critical & every day matters.
Read 7 tweets
8 Dec
FDA Pfizer/BioNTech vaccine efficacy results are great, but aren't nearly as great as presented for severe infections.
Everyone has seen fig below on cases in vaccine (blue) & placebo (red) over time.
Thread.

fda.gov/media/144245/d…
Key aspect of graph: x-axis. It shows days since dose 1 was given. As expected, no difference in total symptomatic cases in vaccine vs placebo for first 7-10d. It takes some time for vaccine to have any effect!
In fact, main reported efficacy of ~95% is for cases starting 7d after 2nd dose. Efficacy for earlier time points are lower: after dose 1, efficacy is 82%.

Why does this matter?
Read 11 tweets
3 Dec
What fraction of people have been infected w/ SARS-CoV-2?
Are cases in some states (e.g. ND) declining b/c they've reached herd immunity?
Some have suggested that a large fraction of the population in these states have been infected & this is important part of decline.
For example @trvrb recently shared @youyanggu estimate that 30% of ND was infected by Nov 8. There has been another 20K cases (+33% compared to 60K then), so this would suggest ~40% have been infected by now. But how are these calculations being done?
@youyanggu nicely provides details of his calculations here: covid19-projections.com/estimating-tru…
& how they result in a ratio of infections/case on a given day (ratio is assumed to decline over time) given a test positivity.
Read 12 tweets
2 Dec
Will vaccination of health care workers (HCWs) lead to accidental silent spreading of COVID-19?

Big possible downside to vaccine allocation recommendations w/out data on whether vaccines reduce infectiousness.
Thread
The justification for vaccinating HCWs is that they are at high risk of exposure from patients & if infected, removing them from workforce has huge impact on care for patients. So vaccinating them 1st seems like an obvious choice, right? Not w/ available data.
We currently know that 2 vaccines (Pfizer/BioNTech, Moderna) reduce symptomatic infections by ~95%. But we have zero data on whether they reduce infectiousness (& primate studies indicate vaccine didn't eliminate it: nejm.org/doi/pdf/10.105…; biorxiv.org/content/10.110…)
Read 11 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!